Pre-IND Phase 2

New Amsterdam Sciences Announces Collaboration with the University of Liverpool to perform additional supportive studies confirming NAS150’s efficacy to treat Rheumatoid Arthritis

NAS will utilize the collected data to support Phase 2 initiatives advancing NAS150 as an RA treatment alternative. The Company’s Platform of Inflammatory Reducing Therapeutics is also intended to be leveraged for the treatment of other autoimmune conditions including Multiple Sclerosis Binghamton, NY – January 5th 2022 — New Amsterdam Sciences, Read more…

By @prwirepro, ago

New Amsterdam Sciences Announces Pre-IND Phase 2 Submission with FDA Coronavirus Treatment Acceleration Program for NAS150 Targeting the Omicron Variant and all variants of SARS-CoV-2

NAS Proposes Phase 2 Clinical Stage Agent Can Be an Effective Treatment and Adjuvant Therapeutic for COVID-19.   NAS150 Application Could Also Potentially Be Applied for COVID-19 Central Nervous System Conditions specifically those related to “Long Haul” conditions. Scottsdale, Arizona, December 3rd 2021 – New Amsterdam Sciences, a privately held Read more…

By @prwirepro, ago

New Amsterdam Sciences Announces Pre-IND Phase 2 Submission with FDA Coronavirus Treatment Acceleration Program for NAS150

Scottsdale, AZ,  May 14th, 2021 – New Amsterdam Sciences, a privately held company, announces the filing of the Company’s newly provided materials and data with the FDA’s coronavirus treatment acceleration program as a pre-Investigation New Drug Phase 2 submission. The FDA submission is for the advancement of the Company’s therapeutic agent Read more…

By @prwirepro, ago